BTG Given “Overweight” Rating at JPMorgan Chase & Co. (BTG)
BTG (LON:BTG)‘s stock had its “overweight” rating reiterated by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Tuesday, Analyst Ratings Net reports. They currently have a GBX 630 ($10.38) price objective on the stock. JPMorgan Chase & Co.’s price target would suggest a potential upside of 3.62% from the company’s current price.
BTG (LON:BTG) traded down 0.25% during mid-day trading on Tuesday, hitting GBX 608.00. The stock had a trading volume of 479,706 shares. BTG has a 52 week low of GBX 313.70 and a 52 week high of GBX 617.50. The stock has a 50-day moving average of GBX 574.6 and a 200-day moving average of GBX 442.2.
Other equities research analysts have also recently issued reports about the stock. Analysts at N+1 Singer reiterated a “sell” rating on shares of BTG in a research note to investors on Thursday, January 2nd. They now have a GBX 490 ($8.08) price target on the stock. Finally, analysts at Nplus1 Brewin initiated coverage on shares of BTG in a research note to investors on Thursday, December 19th. They set a “sell” rating and a GBX 490 ($8.08) price target on the stock. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of GBX 544.13 ($8.97).
BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.